Search
Wisconsin Paid Clinical Trials
A listing of 1261 clinical trials in Wisconsin actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
457 - 468 of 1261
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Location
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Wisconsin is currently home to 1261 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Milwaukee, Madison, Green Bay and Marshfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Therapy
Unique Treatment for High Blood Pressure
Worried about high blood pressure? Think beyond typical high blood pressure treatments.
People who may be candidates for this procedure:
• Are at least 18 years old
• Have been unable to manage their high blood pressure with medications or lifestyle changes alone¹
Learn about a safe and effective procedure that may help reduce high blood pressure. See if you qualify today.
¹ Kandzari DE, et al. J Am Coll Cardiol. Nov 7, 2023;82(19):1809-1823.
People who may be candidates for this procedure:
• Are at least 18 years old
• Have been unable to manage their high blood pressure with medications or lifestyle changes alone¹
Learn about a safe and effective procedure that may help reduce high blood pressure. See if you qualify today.
¹ Kandzari DE, et al. J Am Coll Cardiol. Nov 7, 2023;82(19):1809-1823.
Conditions:
High Blood Pressure
High Blood Pressure (& [Essential Hypertension])
High Blood Pressure (Hypertension).
Hypertension
Essential Hypertension
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Conditions:
Healthy
Healthy Volunteer Study
Featured Offer
Discover Affordable Semaglutide Providers
We Checked the Checkout Page on Every Semaglutide Provider. Here's What We Found.
There's a big difference between the price on a landing page and what you actually pay. We went all the way through checkout so you know exactly what to expect.
📋 5 providers ranked by true monthly cost
💵 Options starting as low as $149/month
🏥 Only licensed providers using FDA-registered pharmacies
⭐ Real Trustpilot scores included — including the ones with mixed reviews
🔒 Includes cancellation policy warnings so you don't get stuck
There's a big difference between the price on a landing page and what you actually pay. We went all the way through checkout so you know exactly what to expect.
📋 5 providers ranked by true monthly cost
💵 Options starting as low as $149/month
🏥 Only licensed providers using FDA-registered pharmacies
⭐ Real Trustpilot scores included — including the ones with mixed reviews
🔒 Includes cancellation policy warnings so you don't get stuck
Conditions:
Weight Loss
Morbid Obesity
Featured Offer
On Medicare? GLP-1's Covered By Medicare Part D [Found Partnership]
Found is now serving individuals who are 65-75 with GLP-1 support for weight care. You need Medicare Part D, must be 18 or older, and must meet BMI criteria when you start GLP-1 therapy:
- BMI 35 or higher, or
- BMI 30–34.99 with at least one qualifying condition (diastolic heart failure, uncontrolled hypertension, CKD stage 3a or higher, prediabetes, prior heart attack or stroke, symptomatic peripheral artery disease), or
- BMI 27–29.99 with prediabetes, prior heart attack/stroke, or symptomatic peripheral artery disease.
- BMI 35 or higher, or
- BMI 30–34.99 with at least one qualifying condition (diastolic heart failure, uncontrolled hypertension, CKD stage 3a or higher, prediabetes, prior heart attack or stroke, symptomatic peripheral artery disease), or
- BMI 27–29.99 with prediabetes, prior heart attack/stroke, or symptomatic peripheral artery disease.
Conditions:
Healthy
Overweight
Overweight and Obesity
Obesity
Overweight or Obesity
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
Recruiting
This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
07/23/2025
Locations: Arthrosi Investigative Site (668), Kenosha, Wisconsin
Conditions: Gout, Arthritis, Gouty, Hyperuricemia, Gout Chronic
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
Recruiting
This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in adults with locally advanced (Stage III), unresectable NSCLC whose disease has not progressed following definitive platinum-based cCRT.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: Research Site, Appleton, Wisconsin
Conditions: Non-Small Cell Lung Cancer
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
Recruiting
The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018, the registry expanded to include recruitment of participants with other chronic fibrosing interstitial lung diseases (ILDs) with progressive phenotype also referred to as progressive fibrosing interstitial lung diseases in the Chronic Fibrosis Interstitial Lung Disease with Progressive Phenotype (ILD-PRO) Registry. When the th... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
07/22/2025
Locations: The Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)
Recruiting
TARGET-NASH is a longitudinal observational cohort study of patients being managed for NASH and related conditions across the entire spectrum NAFLD in usual clinical practice. TARGET-NASH is a research registry of patients with NAFL or NASH within academic and community real-world practices maintained in order to assess the safety and effectiveness of current and future therapies.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
07/22/2025
Locations: University of Wisconsin Hospital & Clinics, Madison, Wisconsin
Conditions: Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
A Longitudinal Observational Study of the Natural History and Management of Patients With HCC
Recruiting
TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of participants with HCC within academic and community real-world practices in order to assess the safety and effectiveness of the entire spectrum of current and future therapies across diverse populations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Hepatocellular Cancer
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
Recruiting
The purpose of this study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS).
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
07/22/2025
Locations: Local Institution - 0033, Milwaukee, Wisconsin
Conditions: Multiple Sclerosis, Relapsing-Remitting
The RECAP2 Study: Midazolam and Psilocybin
Recruiting
The goal of this clinical trial is to learn about the role that inducing neuroplasticity (the brain's ability to adapt and change) plays in the behavioral effects of psilocybin in people who have experienced a mild decline in emotional wellbeing.
Researchers will compare different doses of psilocybin combined with midazolam or placebo to see what dose induces increased wellbeing.
Participants will:
* Receive one of four possible combinations of medications
* Undergo an MRI
* Complete question... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/22/2025
Locations: UW School of Medicine and Public Health, Madison, Wisconsin
Conditions: Psilocybin
Using FAPI PET/MRI to Evaluate Prostate Cancer
Recruiting
The goal of this clinical trial is to gain more information about how FAPI (fibroblast activation protein inhibitor) binds to certain type of cells in the tumor tissue. The main question it aims to answer is how this information can be used to better diagnose and track prostate cancer.
Participants will undergo two PET/MRI scans during two research visits, each of which may last up to 2.5 hours.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Prostate Cancer Metastatic Disease, Prostate Cancers
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
Recruiting
Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of brenetafusp in adult participants who have the appropriate HLA-A2 tissue marker and whose cancer is positive for PRAME.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Select Advanced Solid Tumors
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight.
The maximum duration of this study is up to 61 weeks.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/22/2025
Locations: Wisconsin Center for Advanced Research, Milwaukee, Wisconsin
Conditions: Crohn's Disease, Obesity or Overweight
CBD for Lower Urinary Tract Dysfunction in Spinal Cord Injury
Recruiting
The goal of this feasibility study is to learn whether Cannabidiol (CBD) can improve urinary incontinence and other symptoms in people with recent spinal cord injury (SCI).
Participants will take Epidiolex (purified CBD) for 90 days
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: University of Wisconsin - Madison, Madison, Wisconsin
Conditions: Supra-sacral Spinal Cord Injury, Spinal Cord Injury, Urinary Incontinence
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Recruiting
The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys in participants with T2DM and CKD.
Gender:
ALL
Ages:
Between 30 years and 80 years
Trial Updated:
07/22/2025
Locations: University of Wisconsin-Madison, Madison, Wisconsin
Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Diseases